In relapsed or refractory classical Hodgkin lymphoma patients who have received prior frontline therapy and are candidates for high‑dose therapy and autologous stem‑cell transplantation, when should the BreCADD regimen (brentuximab vedotin, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) be employed?

When to Use BreCADD in Hodgkin Lymphoma

BreCADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) should be used as salvage therapy in relapsed/refractory classical Hodgkin lymphoma patients who are candidates for autologous stem cell transplantation (ASCT), particularly in those with relapsed disease rather than primary refractory disease, and as first-line therapy in older patients (61-75 years) with advanced-stage disease.

Primary Indication: Salvage Therapy Before ASCT

Use BreCADD as second-line salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma patients who are transplant-eligible. The regimen was specifically designed to reduce toxicity while maintaining efficacy compared to escalated BEACOPP 1. Current guidelines recommend various salvage regimens including DHAP, IGEV, or ICE before high-dose chemotherapy and ASCT, but do not specifically list BreCADD as these guidelines predate its development 2.

Patient Selection Criteria

• Relapsed disease patients benefit most: Propensity score-matched analysis shows patients with relapsed disease achieve significantly better 3-year progression-free survival (80% vs 70% with chemotherapy alone, P=0.02), while primary refractory patients show no significant difference (56% vs 62%, P=0.67) 3.

• Stage IV disease: Patients with stage IV disease achieve significantly better outcomes with brentuximab-containing regimens (P=0.015) 3.

• Age considerations: The regimen is feasible and effective across age groups, including patients 61-75 years old 4.

Treatment Protocol

Administer 4-6 cycles of BreCADD based on PET-2 response:

• PET-2 negative patients: Give total of 4 cycles of BreCADD 1, 4.
• PET-2 positive patients: Give 6 cycles of BreCADD 1, 4.
• Dosing: Brentuximab vedotin 1.8 mg/kg (maximum 180 mg) on day 1, etoposide 150 mg/m² on days 2-4, doxorubicin 40 mg/m² on day 2, cyclophosphamide 1250 mg/m² on day 2, dacarbazine 250 mg/m² on days 3-4, and dexamethasone 40 mg on days 2-5 1.

Goal: Achieve complete metabolic response (CMR) before proceeding to ASCT, as achieving negative PET should be the goal of salvage therapy irrespective of protocol 2.

Alternative Indication: First-Line Therapy in Older Patients

Use PET-guided BreCADD as first-line treatment in patients aged 61-75 years with advanced-stage classical Hodgkin lymphoma. This represents a valuable alternative to ABVD in older patients who cannot tolerate BEACOPP (which should not be given to patients >60 years) 2.

Efficacy in Older Patients

• Complete remission rate: 82% (95% CI, 72-90) at end of chemotherapy 4.
• 2-year progression-free survival: 91.5% (95% CI, 85-98) 4.
• 2-year overall survival: 90.8% (95% CI, 84-98) 4.
• Feasibility: 89% of patients received the target number of cycles 4.

Comparison to Standard Salvage Regimens

BreCADD offers comparable efficacy to standard salvage chemotherapy with potentially favorable toxicity profile. No significant differences were observed in pre-ASCT complete metabolic response rates (P=0.69) or overall progression-free survival (P=0.14) compared to chemotherapy alone in the overall population 3. However, the BrECADD regimen was associated with more favorable toxicity compared to BrECAPP (another brentuximab-containing variant), with only 4% experiencing grade 3-4 organ toxicity versus 17% with BrECAPP 1.

Alternative Brentuximab-Based Approaches

While BreCADD is not the only option, consider these alternatives based on patient characteristics:

Sequential Brentuximab Vedotin Monotherapy

Single-agent brentuximab vedotin may be sufficient as salvage therapy before ASCT in select patients 2. PET-adapted approaches using 2-4 cycles of brentuximab vedotin monotherapy followed by platinum-based chemotherapy only for PET-positive patients achieved 65-76% complete remission rates before ASCT 5.

Brentuximab-ICE Combination

Dose-dense brentuximab vedotin combined with ICE (ifosfamide, carboplatin, etoposide) is highly effective with 5-year progression-free survival of 77% and overall survival of 91% 6. This may be especially relevant for patients who relapse after PD-1 inhibitor-based front-line therapy 6.

Common Pitfalls and Caveats

Toxicity Management

• Hematologic toxicity is common: Grade 3-4 leukopenia (96%), thrombocytopenia (86%), anemia (69%), and febrile neutropenia (55%) occur frequently 4.
• Prophylactic G-CSF: Should be administered beginning with Cycle 1 when using brentuximab-containing regimens 7.
• Peripheral neuropathy: Occurs in 32-35% of patients (grade 1-2), with grade 3 in 2%; most cases resolve 1.

Hepatic and Renal Impairment

Dose reduction required for hepatic impairment: Reduce brentuximab vedotin to 1.2 mg/kg (maximum 120 mg) every 3 weeks for mild hepatic impairment (Child-Pugh A); avoid use in moderate or severe hepatic impairment 7.

Post-ASCT Consolidation

Brentuximab vedotin consolidation is recommended following ASCT in patients with poor-risk factors 2. This is separate from the use of BreCADD as salvage therapy and involves single-agent brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles 7.

When NOT to Use BreCADD

• Primary refractory disease: Consider alternative regimens as BreCADD shows no significant benefit over standard chemotherapy in this population 3.
• Severe renal impairment (CrCL <30 mL/min): Avoid brentuximab vedotin 7.
• Patients already receiving front-line brentuximab-containing regimens: The evidence for BreCADD is primarily in patients who received conventional front-line therapy 1, 3, 4.